AIMS: To compare the performance of population-based kinetics with that of directly measured C-peptide kinetics when used to calculate β-cell responsivity indices, and to study people with and without acute insulin resistance to ensure that population-based kinetics apply to all conditions where β-cell function is measured. METHODS: Somatostatin was used to inhibit endogenous insulin secretion in 56 people without diabetes. Subsequently, a C-peptide bolus was administered and the changing concentrations were used to calculate individual kinetic measures of C-peptide clearance. In addition, the participants were studied on 2 occasions in random order using an oral glucose tolerance test (OGTT). On one occasion, free fatty acid elevation, to cause insulin resistance, was achieved by infusion of Intralipid + heparin. The Disposition Index (DI) was then estimated by the oral minimal model using either population-based or individual C-peptide kinetics. RESULTS: There were marked differences in the exchange variables (k 12 and k 21 ) of the model describing C-peptide kinetics, but smaller differences in the fractional clearance; that is, the irreversible loss from the accessible compartment (k 01 ), obtained from population-based estimates compared with experimental measurement. Because it is predominantly influenced by k 01 , DI estimated using individual kinetics correlated well with DI estimated using population-based kinetics. CONCLUSIONS: These data support the use of population-based measures of C-peptide kinetics to estimate β-cell function during an OGTT.
AIMS: To compare the performance of population-based kinetics with that of directly measured C-peptide kinetics when used to calculate β-cell responsivity indices, and to study people with and without acute insulin resistance to ensure that population-based kinetics apply to all conditions where β-cell function is measured. METHODS: Somatostatin was used to inhibit endogenous insulin secretion in 56 people without diabetes. Subsequently, a C-peptide bolus was administered and the changing concentrations were used to calculate individual kinetic measures of C-peptide clearance. In addition, the participants were studied on 2 occasions in random order using an oral glucose tolerance test (OGTT). On one occasion, free fatty acid elevation, to cause insulin resistance, was achieved by infusion of Intralipid + heparin. The Disposition Index (DI) was then estimated by the oral minimal model using either population-based or individual C-peptide kinetics. RESULTS: There were marked differences in the exchange variables (k 12 and k 21 ) of the model describing C-peptide kinetics, but smaller differences in the fractional clearance; that is, the irreversible loss from the accessible compartment (k 01 ), obtained from population-based estimates compared with experimental measurement. Because it is predominantly influenced by k 01 , DI estimated using individual kinetics correlated well with DI estimated using population-based kinetics. CONCLUSIONS: These data support the use of population-based measures of C-peptide kinetics to estimate β-cell function during an OGTT.
Authors: Chiara Dalla Man; Francesco Micheletto; Airani Sathananthan; Robert A Rizza; Adrian Vella; Claudio Cobelli Journal: Am J Physiol Endocrinol Metab Date: 2010-02-23 Impact factor: 4.310
Authors: Struan F A Grant; Gudmar Thorleifsson; Inga Reynisdottir; Rafn Benediktsson; Andrei Manolescu; Jesus Sainz; Agnar Helgason; Hreinn Stefansson; Valur Emilsson; Anna Helgadottir; Unnur Styrkarsdottir; Kristinn P Magnusson; G Bragi Walters; Ebba Palsdottir; Thorbjorg Jonsdottir; Thorunn Gudmundsdottir; Arnaldur Gylfason; Jona Saemundsdottir; Robert L Wilensky; Muredach P Reilly; Daniel J Rader; Yu Bagger; Claus Christiansen; Vilmundur Gudnason; Gunnar Sigurdsson; Unnur Thorsteinsdottir; Jeffrey R Gulcher; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2006-01-15 Impact factor: 38.330
Authors: Chiara Dalla Man; Gerlies Bock; Paula D Giesler; Denise B Serra; Monica Ligueros Saylan; James E Foley; Michael Camilleri; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: Diabetes Care Date: 2008-10-17 Impact factor: 17.152
Authors: Marcello C Laurenti; Adrian Vella; Ron T Varghese; James C Andrews; Anu Sharma; Nana Esi Kittah; Robert A Rizza; Aleksey Matveyenko; Giuseppe De Nicolao; Claudio Cobelli; Chiara Dalla Man Journal: Am J Physiol Endocrinol Metab Date: 2019-02-26 Impact factor: 4.310
Authors: Bradley Anderson; Paula Carlson; Marcello Laurenti; Adrian Vella; Michael Camilleri; Anshuman Desai; Kelly Feuerhak; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2019-11-05 Impact factor: 3.598
Authors: Marcello C Laurenti; Chiara Dalla Man; Ron T Varghese; James C Andrews; Robert A Rizza; Aleksey Matveyenko; Giuseppe De Nicolao; Claudio Cobelli; Adrian Vella Journal: JCI Insight Date: 2020-04-09
Authors: Marcello C Laurenti; Praveer Arora; Chiara Dalla Man; James C Andrews; Robert A Rizza; Aleksey Matveyenko; Kent R Bailey; Claudio Cobelli; Adrian Vella Journal: Physiol Rep Date: 2022-07
Authors: Marcello C Laurenti; Chiara Dalla Man; Ron T Varghese; James C Andrews; John G Jones; Cristina Barosa; Robert A Rizza; Aleksey Matveyenko; Giuseppe De Nicolao; Kent R Bailey; Claudio Cobelli; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Marcello C Laurenti; Adrian Vella; Jon D Adams; Daniel J Schembri Wismayer; Aoife M Egan; Chiara Dalla Man Journal: Am J Physiol Endocrinol Metab Date: 2020-11-02 Impact factor: 4.310
Authors: Michele Schiavon; David Herzig; Matthias Hepprich; Marc Y Donath; Lia Bally; Chiara Dalla Man Journal: Front Endocrinol (Lausanne) Date: 2021-03-15 Impact factor: 5.555